Efgartigimod, as a novel FcRn antagonist, accelerates the degradation of pathogenic IgG antibodies and has demonstrated favorable safety and efficacy in the treatment of myasthenia gravis. This evidence concerns the gene FCGRT and myasthenia gravis.